参考文献/References:
[1] Bonewald LF, Kneissel M, Johnson M. Preface: the osteocyte[J].Bone,2013,54(2):181.DOI:10.1016/j.bone.2013.02.018.
[2] Ducy P, Amling M, Takeda S,et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass[J].Cell,2000,100(2):197-207.
[3] Esen E, Chen J, Karner CM,et al. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation[J].Cell Metab,2013,17(5):745-755. DOI:10.1016/j.cmet.2013.03.017.
[4] Bonewald LF, Wacker MJ. FGF23 production by osteocytes[J].Pediatr Nephrol,2013,28(4):563-568. DOI:10.1007/s00467-012-2309-3.
[5] Nakashima T, Hayashi M, Fukunaga T,et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression[J].Nat Med,2011,17(10):1231-1234. DOI:10.1038/nm.2452.
[6] Compton JT, Lee FY. A review of osteocyte function and the emerging importance of sclerostin[J].J Bone Joint Surg Am,2014,96(19):1659-1668. DOI:10.2106/JBJS.M.01096.
[7] Riddle RC, Frey JL, Tomlinson RE,et al. Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis[J].Mol Cell Biol,2014,34(10):1850-1862. DOI:10.1128/MCB.00075-14.
[8] Oury F, Sumara G, Sumara O,et al. Endocrine regulation of male fertility by the skeleton[J].Cell,2011,144(5):796-809. DOI:10.1016/j.cell.2011.02.004.
[9] Lu Y, Liu X, Jiao Y,et al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα[J].J Clin Invest,2014,124(8):3501-3513. DOI:10.1172/JCI74438.
[10] Takayanagi H. Osteoimmunology in 2014: two-faced immunology-from osteogenesis to bone resorption[J].Nat Rev Rheumatol,2015,11(2):74-76.DOI:10.1038/nrrheum.2014.219.
[11] Spiegelman BM. Banting Lecture 2012: regulation of adipogenesis: toward new therapeutics for metabolic disease[J].Diabetes,2013,62(6):1774-1782. DOI:10.2337/db12-1665.
[12] Vella A, Drucker DJ. Multiple endocrine neoplasia. In:Melmed S, Polonsky PR, eds. Williams Textbook of Endocrinology 12th ed. 2012, 1697-1718.
[13] Reimann F, Habib AM, Tolhurst G,et al. Glucose sensing in L cells: a primary cell study[J].Cell Metab,2008,8(6):532-539. DOI:10.1016/j.cmet.2008.11.002.
[14] Yi P, Park JS, Melton DA. Retraction notice to: betatrophin: a hormone that controls pancreatic β cell proliferation[J]. Cell, 2017,168(1-2):326. DOI:10.1016/j.cell.2016.12.017.
[15] 田媛, 谭莉莉, 王玉冰, 等. 非酒精性脂肪肝患者血浆成纤维细胞生长因子21水平与肥胖、脂代谢及胰岛素抵抗的相关性[J]. 中国老年学杂志, 2016, 36(15): 3761-3763. DOI:10.3969/j.issn.1005-9202.2016.15.071.
[16] 徐杰, 王艳. 2型糖尿病患者的血脂水平、血清胎球蛋白A 与糖尿病肾病的相关性研究[J]. 湖南师范大学学报(医学版), 2016, 13(4): 55-57.
[17] Li J, Chi Y, Wang C,et al. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway[J].Hepatology,2011,53(6):1906-1916. DOI:10.1002/hep.24295.
[18] Preis SR, Massaro JM, Robins SJ,et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study[J].Obesity(Silver Spring),2010,18(11):2191-2198.DOI:10.1038/oby.2010.59.
[19] Makimura H, Stanley T, Mun D,et al. The effects of central adiposity on growth hormone(GH)response to GH-releasing hormone-arginine stimulation testing in men[J].J Clin Endocrinol Metab,2008,93(11):4254-4260. DOI:10.1210/jc.2008-1333.
[20] Koutkia P, Meininger G, Canavan B,et al. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy[J].Am J Physiol Endocrinol Metab,2004,286(2):E296-E303. DOI:10.1152/ajpendo.00335.2003.
[21] Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell[J].Endocrinol Metab Clin North Am,2008,37(3):753-768, x-xi. DOI:10.1016/j.ecl.2008.07.002.
[22] Donath MY, Böni-Schnetzler M, Ellingsgaard H,et al. Cytokine production by islets in health and diabetes: cellular origin, regulation and function[J].Trends Endocrinol Metab,2010,21(5):261-267. DOI:10.1016/j.tem.2009.12.010.
[23] Ferrannini E, Natali A, Camastra S,et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance[J].Diabetes,2013,62(5):1730-1737. DOI:10.2337/db12-0707.
[24] Teles MG, Bianco SD, Brito VN,et al. A GPR54-activating mutation in a patient with central precocious puberty[J].N Engl J Med,2008,358(7):709-715.DOI:10.1056/NEJMoa073443.
[25] 袁媛, 郑梅玲. 多肽类激素kisspeptin的生殖内分泌功能研究进展[J]. 中华妇幼临床医学杂志(电子版), 2016, 12(4): 489-492. DOI:10.3877/cma.j.issn.1673-5250.2016.04.023.
[26] Raivio T, Falardeau J, Dwyer A,et al. Reversal of idiopathic hypogonadotropic hypogonadism[J].N Engl J Med,2007,357(9):863-873. DOI:10.1056/NEJMoa066494.
[27] Ong KK, Elks CE, Li S,et al. Genetic variation in LIN28B is associated with the timing of puberty[J].Nat Genet,2009,41(6):729-733.DOI:10.1038/ng.382.
[28] Varela A, Chouinard L, Lesage E, et al. One year of abaloparatide, a selective peptide activator of the PTH1 recepor, increased bone mass and strength in ovariectomized rats[J]. Bone, 2017, 95:143-150.DOI:10.1016/j.bone.2016.11.027.
[29] McClung MR, Grauer A, Boonen S,et al. Romosozumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2014,370(5):412-420.DOI:10.1056/NEJMoa1305224.
[30] Cummings SR, San Martin J, McClung MR,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J].N Engl J Med,2009,361(8):756-765. DOI:10.1056/NEJMoa0809493.
[31] Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children[J].J Clin Endocrinol Metab,2010,95(7):3260-3267. DOI:10.1210/jc.2009-2546.
[32] Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2[J].Annu Rev Physiol,2014,76:561-583. DOI:10.1146/annurev-physiol-021113-170317.
[33] Tooley JE, Waldron-Lynch F, Herold KC. New and future immunomodulatory therapy in type 1 diabetes[J].Trends Mol Med,2012,18(3):173-181. DOI:10.1016/j.molmed.2012.01.001.
[34] Russell SJ, El-Khatib FH, Sinha M,et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes[J].N Engl J Med,2014,371(4):313-325. DOI:10.1056/NEJMoa1314474.
[35] Guariguata L, Whiting DR, Hambleton I,et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J].Diabetes Res Clin Pract,2014,103(2):137-149. DOI:10.1016/j.diabres.2013.11.002.
[36] Stanley TL, Feldpausch MN, Oh J,et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial[J].JAMA,2014,312(4):380-389. DOI:10.1001/jama.2014.8334.
[37] Herold KC, Usmani-Brown S, Ghazi T,et al. β cell death and dysfunction during type 1 diabetes development in at-risk individuals[J].J Clin Invest,2015,125(3):1163-1173. DOI:10.1172/JCI78142.
[38] Papapoulos SE. Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis[J].Nat Rev Endocrinol,2015,11(2):69-70. DOI:10.1038/nrendo.2014.214.